UpdatesPress Release
OneSource saw strong Q4FY26 performance with Revenue at ₹428.2 Cr (+47% QoQ) and EBITDA at ₹91.9 Cr (5x+ QoQ), driven by semaglutide launches.
Onesource Specialty Pharma LimitedONESOURCE · Filed with the exchange
It reaffirms FY28 guidance of ~₹3596 Cr organic revenue and 40% EBITDA margin.
Steriscience asset acquisition is paused until post FY28.
No comments yet. Be the first.